# A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus

> **NCT07347080** · EARLY_PHASE1 · RECRUITING · sponsor: **The First Affiliated Hospital of Henan University of Science and Technology** · enrollment: 9 (estimated)

## Conditions studied

- T2DM

## Interventions

- **DRUG:** Exenatide Circular RNA-Lipid Nanoparticle Injection（ CR059））

## Key facts

- **NCT ID:** NCT07347080
- **Lead sponsor:** The First Affiliated Hospital of Henan University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-20
- **Primary completion:** 2026-08-31
- **Final completion:** 2026-08-31
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07347080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07347080, "A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07347080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*